Dose-escalating vinblastine for the treatment of canine mast cell tumour.
The purpose of this study was to evaluate the short-term adverse events (AEs) in dogs with mast cell tumours (MCT) receiving prednisone and dose-escalating vinblastine (VBL). Twenty-four dogs were treated with intravenous VBL starting at 2 mg m(-2) and then escalating in weekly increments to 2.33, 2.67 and 3 mg m(-2). AEs were graded using a standardized scoring system. No dogs receiving 2 or 2.33 mg m(-2) experienced grade 3 or 4 AEs. Among the dogs, 9.5 and 5.9% had grade 3 or 4 AEs at dosages of 2.67 and 3 mg m(-2), respectively. Serious AEs included neutropaenia (n = 3) and vomiting (n = 1), only one of which required hospitalization. These data indicate that VBL chemotherapy may be safe to administer at higher than the traditional 2 mg m(-2) dosage for dogs with MCT. Randomized prospective trials are necessary to establish whether dose escalation will translate into improved response rates when compared with the standard 2 mg m(-2) dosage.
Vickery
K R
KR
The Animal Cancer Center, Colorado State University, Fort Collins, CO 80523-1620, USA.
Wilson
H
H
Vail
D M
DM
Thamm
D H
DH
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D012515:Mast-Cell Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D009362:Neoplasm Metastasis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014747:Vinblastine